Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Slides:

Advertisements

Similar presentations

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Advertisements

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

Dose-escalation patient response.

IDH1 mutant glioma cells are sensitive to TMZ

Clonal evolution of resistance to sequential ALK inhibitor therapy.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

A, baseline and 4-week PET scan from patient 2 (MET c

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Serial imaging while on immunosuppressive therapy (two subjects).

Antitumor activity of BAY in patient-derived tumor models.

Precontrast coronal T1-weighted view shows metastatic nodules (long arrows) from breast cancer in the vicinity of the left BPL and another metastatic mass.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Clinical responses in patients.

NrasG12D induces CNS tumors in mice.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Proposed spiral model for prostate cancer progression.

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Gamma camera images at 72 h of patient with T3N0M0 squamous cell cancer of the tongue base (patient 14). Gamma camera images at 72 h of patient with T3N0M0.

Duration of treatment and intervals of radiographic and ctDNA response

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

MDC/CCL22 and MMP-2 factors are found in the melanoma microenvironment and correlate with pDC accumulation and early relapse. MDC/CCL22 and MMP-2 factors.

Heterogeneous effects of fulvestrant were observed between lesions within individuals. Heterogeneous effects of fulvestrant were observed between lesions.

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Location of the ER mutations and frequencies per cohort.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Change in FES uptake in the tumor during fulvestrant treatment.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Representative patient responses to ulixertinib.

Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for.

Genomic determinants of response to cytotoxic chemotherapy.

Serial CT scan images from patient with a partial response.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic imaging for patient A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic.

Mechanism by which flavopiridol induces cell cycle arrest and apoptosis in rhabdoid tumor cells. Mechanism by which flavopiridol induces cell cycle arrest.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

Core melanoma escape pathways during disease progression on BRAF inhibitor therapy. Core melanoma escape pathways during disease progression on BRAF inhibitor.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

CD36 expression in tissue adjacent and distal to the tumor.

Curative effect of W+T treatment in vivo.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

Therapeutic efficacy of MEK and RAF inhibition in patients with MAP2K1- and ARAF-mutant systemic histiocytic neoplasms. Therapeutic efficacy of MEK and.

AXL is not necessary for maintenance of intrinsic resistance.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Orbital infiltration. Orbital infiltration. A, Soft tissue is seen in the posterior left orbit in this patient with metastatic disease to the bone. The.

Presentation transcript:

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Arrows indicate the tumor in the liver (left) and spleen (right) at baseline (A) and after 4 cycles of treatment (B). Kimberly Brown Dahlman et al. Cancer Discovery 2012;2:791-797 ©2012 by American Association for Cancer Research